Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter

Despite the innate limitations of a retrospective design and relatively small size of the ADT+D cohort, this analysis suggests that elderly men receiving AA or Enza as first-line therapy for mCRPC have similar survival outcomes and tolerability, regardless of previous D for mCSPC.

Authors

Institutions

Publication Details

Journal
Clinical Genitourinary Cancer
Published
2024-08-09
DOI
https://doi.org/10.1016/j.clgc.2024.102185
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter

Alessandra Damassi, Giuseppe Fotia, Heather M. McClure, Talal El Zarif et al.
Clinical Genitourinary Cancer
Prostate Cancer Treatment and Research
article

Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter

Alessandra Damassi, Giuseppe Fotia, Heather M. McClure, Talal El Zarif, Andrea Malgeri, Edoardo Francini, Praful Ravi, Elisa Zanardi, Daniel Yick Chin Heng, Ricardo Pereira Mestre, Gian Paolo Spinelli, Richard M. Lee‐Ying, Veronica Murianni, Sabrina Rossetti, Pier Vitale Nuzzo, Antonio Russo, Giuseppe Procopio, Mikol Modesti, Matthew P. Davidsohn, Ugo De Giorgi, Anna Patrikidou, Thiago Martins Oliveira, Calogero Saieva, Charles Vauchier, Sandro Pignata, Loana Bueno Valença, Daniele Santini, Marc Eid, Christopher Sweeney
article en

Abstract

Despite the innate limitations of a retrospective design and relatively small size of the ADT+D cohort, this analysis suggests that elderly men receiving AA or Enza as first-line therapy for mCRPC have similar survival outcomes and tolerability, regardless of previous D for mCSPC.

Clinical Genitourinary CancerVol. 22(5)
Harvard University (US), Cornell University (US), Policlinico Umberto I (IT), Prevention Institute (US), Institut Gustave Roussy (FR), National Cancer Centre Japan (JP), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Institute of Oncology Research (CH), D’Or Institute for Research and Education (BR), Dana-Farber Cancer Institute (US), Centre for Cancer Biology (AU), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Campus Bio Medico University Hospital (IT), Ospedale Policlinico San Martino (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Ospedali Riuniti Umberto I (IT), Weill Cornell Medicine (US), University of Florence (IT), The University of Adelaide (AU), Sapienza University of Rome (IT), University of Palermo (IT)
Openalex Percentile: Top 76%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.